668 related articles for article (PubMed ID: 33039464)
1. High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids.
Shinozawa T; Kimura M; Cai Y; Saiki N; Yoneyama Y; Ouchi R; Koike H; Maezawa M; Zhang RR; Dunn A; Ferguson A; Togo S; Lewis K; Thompson WL; Asai A; Takebe T
Gastroenterology; 2021 Feb; 160(3):831-846.e10. PubMed ID: 33039464
[TBL] [Abstract][Full Text] [Related]
2. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids.
Mun SJ; Ryu JS; Lee MO; Son YS; Oh SJ; Cho HS; Son MY; Kim DS; Kim SJ; Yoo HJ; Lee HJ; Kim J; Jung CR; Chung KS; Son MJ
J Hepatol; 2019 Nov; 71(5):970-985. PubMed ID: 31299272
[TBL] [Abstract][Full Text] [Related]
3. A human liver organoid screening platform for DILI risk prediction.
Zhang CJ; Meyer SR; O'Meara MJ; Huang S; Capeling MM; Ferrer-Torres D; Childs CJ; Spence JR; Fontana RJ; Sexton JZ
J Hepatol; 2023 May; 78(5):998-1006. PubMed ID: 36738840
[TBL] [Abstract][Full Text] [Related]
4. High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells.
Sirenko O; Hesley J; Rusyn I; Cromwell EF
Assay Drug Dev Technol; 2014; 12(1):43-54. PubMed ID: 24229356
[TBL] [Abstract][Full Text] [Related]
5. Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening.
Gómez-Lechón MJ; Tolosa L
Arch Toxicol; 2016 Sep; 90(9):2049-2061. PubMed ID: 27325232
[TBL] [Abstract][Full Text] [Related]
6. Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease.
Ramli MNB; Lim YS; Koe CT; Demircioglu D; Tng W; Gonzales KAU; Tan CP; Szczerbinska I; Liang H; Soe EL; Lu Z; Ariyachet C; Yu KM; Koh SH; Yaw LP; Jumat NHB; Lim JSY; Wright G; Shabbir A; Dan YY; Ng HH; Chan YS
Gastroenterology; 2020 Oct; 159(4):1471-1486.e12. PubMed ID: 32553762
[TBL] [Abstract][Full Text] [Related]
7. In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review.
Cheng Y; Woolf TF; Gan J; He K
Chem Biol Interact; 2016 Aug; 255():23-30. PubMed ID: 26683212
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse.
Zhang J; He K; Cai L; Chen YC; Yang Y; Shi Q; Woolf TF; Ge W; Guo L; Borlak J; Tong W
Chem Biol Interact; 2016 Aug; 255():45-54. PubMed ID: 27000539
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes.
Terelius Y; Figler RA; Marukian S; Collado MS; Lawson MJ; Mackey AJ; Manka D; Qualls CW; Blackman BR; Wamhoff BR; Dash A
Chem Biol Interact; 2016 Aug; 255():31-44. PubMed ID: 26626330
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Drug-Induced Liver Injury in Micropatterned Co-cultures Containing iPSC-Derived Human Hepatocytes.
Ware BR; Berger DR; Khetani SR
Toxicol Sci; 2015 Jun; 145(2):252-62. PubMed ID: 25716675
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Screening to Evaluate Inhibition of Bile Acid Transporters Using Human Hepatocytes Isolated From Chimeric Mice.
Kohara H; Bajaj P; Yamanaka K; Miyawaki A; Harada K; Miyamoto K; Matsui T; Okai Y; Wagoner M; Shinozawa T
Toxicol Sci; 2020 Feb; 173(2):347-361. PubMed ID: 31722436
[TBL] [Abstract][Full Text] [Related]
12. In vitro bile acid-dependent hepatocyte toxicity assay system using human induced pluripotent stem cell-derived hepatocytes: Current status and disadvantages to overcome.
Sakai Y; Iwao T; Susukida T; Nukaga T; Takemura A; Sekine S; Ito K; Matsunaga T
Drug Metab Pharmacokinet; 2019 Aug; 34(4):264-271. PubMed ID: 31285099
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.
Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M
Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588
[TBL] [Abstract][Full Text] [Related]
14. Human chemically-derived hepatic progenitors (hCdHs) as a source of liver organoid generation: Application in regenerative medicine, disease modeling, and toxicology testing.
Salas-Silva S; Kim Y; Kim TH; Kim M; Seo D; Choi J; Factor VM; Seo HR; Song Y; Choi GS; Jung YK; Kim K; Lee KG; Jeong J; Shin JH; Choi D
Biomaterials; 2023 Dec; 303():122360. PubMed ID: 38465578
[TBL] [Abstract][Full Text] [Related]
15. Establishment of human induced pluripotent stem cell-derived hepatobiliary organoid with bile duct for pharmaceutical research use.
Wang L; Koui Y; Kanegae K; Kido T; Tamura-Nakano M; Yabe S; Tai K; Nakajima Y; Kusuhara H; Sakai Y; Miyajima A; Okochi H; Tanaka M
Biomaterials; 2024 Oct; 310():122621. PubMed ID: 38815455
[TBL] [Abstract][Full Text] [Related]
16. Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency.
Li CZ; Ogawa H; Ng SS; Chen X; Kishimoto E; Sakabe K; Fukami A; Hu YC; Mayhew CN; Hellmann J; Miethke A; Tasnova NL; Blackford SJI; Tang ZM; Syanda AM; Ma L; Xiao F; Sambrotta M; Tavabie O; Soares F; Baker O; Danovi D; Hayashi H; Thompson RJ; Rashid ST; Asai A
JHEP Rep; 2022 Apr; 4(4):100446. PubMed ID: 35284810
[TBL] [Abstract][Full Text] [Related]
17. Dissecting the molecular pathophysiology of drug-induced liver injury.
Ye H; Nelson LJ; Gómez Del Moral M; Martínez-Naves E; Cubero FJ
World J Gastroenterol; 2018 Apr; 24(13):1373-1385. PubMed ID: 29632419
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
Zhang J; Doshi U; Suzuki A; Chang CW; Borlak J; Li AP; Tong W
Chem Biol Interact; 2016 Aug; 255():3-11. PubMed ID: 26581450
[TBL] [Abstract][Full Text] [Related]
19. Puromycin-based purification of cells with high expression of the cytochrome P450 CYP3A4 gene from a patient with drug-induced liver injury (DILI).
Miyata S; Saku N; Akiyama S; Javaregowda PK; Ite K; Takashima N; Toyoda M; Yura K; Kimura T; Nishina H; Nakazawa A; Kasahara M; Nonaka H; Kiyono T; Umezawa A
Stem Cell Res Ther; 2022 Jan; 13(1):6. PubMed ID: 35012658
[TBL] [Abstract][Full Text] [Related]
20. A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery.
Hafey MJ; Houle R; Tanis KQ; Knemeyer I; Shang J; Chen Q; Baudy A; Monroe J; Sistare FD; Evers R
Drug Metab Dispos; 2020 Nov; 48(11):1147-1160. PubMed ID: 32943412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
